Friday, 16 October 2026European Markets

MKB Nedsense Stock Went Down By Over 26% So Far On Friday

Loading stream...

(VIANEWS) - Shares of MKB Nedsense (AEX-Index: NEDSE.AS) slid by a staggering 26.4% to €0.09 at 14:08 EST on Friday, after two consecutive sessions in a row of losses. AEX-Index is dropping 0.11% to €759.77, following the last session's upward trend. This seems, so far, a somewhat down trend exchanging session today.

About MKB Nedsense

MKB Nedsense N.V. engages in the finance and lending of money to natural persons and legal entities. It also provides guarantees and/or other securities towards third parties for its obligations and/or for obligations for companies in the investment portfolio. The company was formerly known as Nedsense Enterprises N.V. MKB Nedsense N.V. was founded in 1999 and is based in Bussum, the Netherlands.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, MKB Nedsense's stock is considered to be overbought (>=80).

Volume

Today's last reported volume for MKB Nedsense is 367906 which is 2090.44% above its average volume of 16796.

Volatility

MKB Nedsense's last week, last month's, and last quarter's current intraday variation average was a negative 2.84%, a negative 0.28%, and a positive 4.01%.

MKB Nedsense's highest amplitude of average volatility was 2.84% (last week), 4.41% (last month), and 4.01% (last quarter).

More news about MKB Nedsense (NEDSE.AS).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com